ARAljoscha Rastan

Aljoscha Rastan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aljoscha Rastan has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Challenging anatomy, how to treat or not to treat?

    by Thomas Zeller, Aljoscha Rastan, Roland Macharzina, Elias Noory

    The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)


  • Sirolimus-Eluting Stents for Treatment of Infrapopliteal Arteries Reduce Clinical Event Rate Compared to Bare-Metal Stents

    by Aljoscha Rastan, Klaus Brechtel, Hans Krankenberg, Rainer Zahorsky, Gunnar Tepe, Elias Noory, Uwe Schwarzwälder, Roland Macharzina, Thomas Schwarz, Karlheinz Bürgelin, et al.


  • Drug-eluting stents for treatment of focal infrapopliteal lesions

    by Aljoscha Rastan, Elias Noory, Thomas Zeller

    We have investigated the role of drug-eluting stents on patency rates after treatment of focal infrapopliteal lesions in patients with intermittent claudication and critical limb ischemia. Reports indicate that drug-eluting stents reduce the risk of restenosis after percutaneous infrapopliteal artery revascularization. A Pub Med, EMBASE, Cochrane database review search of non-randomized studies investigating patency rates, target lesion revascularisation rates, limb salvage rates and mortality rates in an up to 3-year follow-up period after drug-eluting stent placement was conducted. In addition, preliminary results of randomized studies comparing drug-eluting stents with bare-metal stents and plain balloon angioplasty in treatment of focal infrapopliteal lesions were included in this review. A total of 1039 patients from 10 non-randomized and randomized studies were included. Most commonly used drug-eluting stents were sirolimus-eluting. The mean follow-up period was 12.6 (range 8 - 24). The mean 1-year primary patency rate was 86 ± 5 %. The mean target lesion revascularization rate and limb salvage rate was 9.9 ± 5 % and 96.6 %±4 %, respectively. Results from non-randomized and preliminary results from prospective, randomized trials show a significant advantage for drug-eluting stents in comparison to plain balloon angioplasty and bare-metal stents concerning target lesion patency and in parts target lesion revascularisation. No trial reveals an advantage for drug-eluting stents with regard to limb salvage and mortality.


  • Open Access

    Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial

    by Aljoscha Rastan, Gunnar Tepe, Hans Krankenberg, Rainer Zahorsky, Ullrich Beschorner, Elias Noory, Sebastian Sixt, Thomas Schwarz, Klaus Brechtel, Catherine Böhme, et al.

    Preliminary reports indicate that sirolimus-eluting stents reduce the risk of restenosis after percutaneous infrapopliteal artery revascularization. We conducted a prospective, randomized, multi-centre, double-blind trial comparing a polymer-free sirolimus-eluting stent with a placebo-coated bare-metal stent in patients with either intermittent claudication or critical limb ischaemia who had a de-novo lesion in an infrapopliteal artery. 161 patients were included in this trial. The mean target lesion length was 31 ± 9 mm. The main study endpoint was the 1-year primary patency rate, defined as freedom from in-stent-restenosis (luminal narrowing of ≥50%) detected with duplex ultrasound if not appropriate with angiography. Secondary endpoints included the 6-month primary patency rate, secondary patency rate, and changes in Rutherford–Becker classification after 1 year. Twenty-five (15.5%) patients died during the follow-up period. One hundred and twenty-five patients reached the 1-year examinations. The 1-year primary patency rate was significantly higher in the sirolimus-eluting stent group (80.6%) than in the bare-metal stent group (55.6%, P= 0.004), and the 1-year secondary patency rates were 91.9 and 71.4% (P= 0.005), respectively. The median (interquartile range) change in Rutherford–Becker classification after 1 year was −2 (−3 to −1) in the sirolimus-eluting stent group and −1 (−2 to 0) in the bare-metal stent group, respectively (P= 0.004). Mid-term patency rates of focal infrapopliteal lesions are substantially improved with sirolimus-eluting stent compared with bare-metal stent. Corresponding to the technical results, the changes in Rutherford–Becker classification reveal a significant advantage for the sirolimus-eluting stent. Clinical Trial Registration Information: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00664963.


  • Primary Use of Sirolimus-Eluting Stents in the Infrapopliteal Arteries

    by Aljoscha Rastan, Uwe Schwarzwälder, Elias Noory, Faical Haj Taieb, Ullrich Beschorner, Sebastian Sixt, Karlheinz Bürgelin, Pietro Amantea, Franz-Josef Neumann, Thomas Zeller

    Purpose: To report 12-month outcomes following application of sirolimus-eluting stents (SES) in infrapopliteal arteries in patients with chronic limb ischemia. ...


  • VIPER-2:A Prospective, Randomized Single-Center Comparison of 2 Different Closure Devices With a Hemostatic Wound Dressing for Closure of Femoral Artery Access Sites

    by Aljoscha Rastan, Sebastian Sixt, Uwe Schwarzwälder, Thomas Schwarz, Ulrich Frank, Karlheinz Bürgelin, Volker Pochert, Elias Noory, Pietro Amantea, Daniel Gremmelmaier, et al.

    Purpose: To report the outcome of a prospective randomized safety and performance trial of 2 access site closure devices versus a wound dressing. Methods: Betwe...


    • 1 February 2007
      • Vol. 2  (4) , 444-51

    Endovascular therapy of chronic mesenteric ischaemia.

    by Thomas Zeller, Aljoscha Rastan, Uwe Schwarzwälder, Thomas Schwarz, Ulrich Frank, Karlheinz Bürgelin, Sebastian Sixt, Christian Müller, Uwe Rothenpieler, Peter-Christian Flügel, et al.

    Chronic mesenteric ischaemia (CMI) is associated with a high morbidity and mortality. Most likely causes of CMI are atherosclerosis, external compression (Dunbar Syndrome) and vasculitis. We report on our experience with endovascular stent therapy. Between Sept. 1998 and Dec. 2005 we treated 21 consecutive patients (52% male; mean age 64+/-15 years, range 18-81 years) due to symptomatic CMI. A total of 34 interventions with 41 treated lesions were performed. Aetiology of vessel obstruction was atherosclerosis in 14 patients (67%), Dunbar syndrome in 3 patients (14%), chronic type B aortic dissection in 2 patients (9%), Takayasu's arteritis in 1 patient (4.5%), external compression following abdominal surgery in 1 patient (4.5%). Target lesions were celiac trunk (n=16), superior mesenteric artery (n=24), and inferior mesenteric artery (n=1). Twenty-two percent (n=9) of the lesions were total occlusions. The patients underwent serial follow-up duplex examinations before discharge and every 6 months thereafter or in case of symptom recurrence. Thirty-one of the 34 (91%) interventions were technically successful (37/41 lesions; 90%). Two of these 4 lesions were treated successfully using another approach in a second intervention. Brachial access was used in 16/34 cases (47%). One or more stents were placed in 29/34 interventions (85%) and 35/41 lesions. In 3 cases, in-stent restenosis was treated with balloon angioplasty alone, and in two cases, 3 occlusions could not be reopened. During 6 interventions, drug eluting stents were placed. All patients treated successfully were free of symptoms immediately after the intervention with recurrence of symptoms in case of restenosis. After a mean follow-up of 31+/-26 (range 0-87) months restenosis was detected in 6 patients (29%). Two major complications occurred which were treated without permanent sequelae. Stenoses of mesenteric arteries resulting in symptomatic CMI can be treated successfully with stent-angioplasty; for anatomical reasons, the brachial approach should be considered. Recanalisation of total obstructions is feasible if a stump of the occluded artery is detectable. Restenosis is frequent and can easily be treated with balloon angioplasty or stent-in-stent placement.